Answers are grounded in this paper and cite their sources.
Breast cancer remains one of the leading causes of cancer-related mortality worldwide, highlighting the need for novel therapeutic strategies capable of improving treatment efficacy and minimizing adverse effects. In this context, postbiotics have emerged as promising microbiome-derived bioactive preparations with potential applications in cancer therapy. The present study investigated the biological activity of postbiotics obtained from Lactiplantibacillus plantarum PFA2018AU and Bifidobacterium longum W11 against human breast cancer cells. The biochemical composition of both postbiotics was first characterized by 1H-NMR-based metabolomic analysis, revealing distinct metabolite profiles. Their biological effects were subsequently evaluated in MCF-7 and MDA-MB-231 breast cancer cell lines, as well as in non-tumorigenic HaCaT cells. Both postbiotics exhibited different effects on breast cancer cell lines and HaCaT keratinocytes under the tested experimental conditions, significantly reducing the viability and proliferative potential of breast cancer cells, while no significant effects were observed in HaCaT cells. These effects were associated with increased intracellular oxidative stress, induction of apoptosis, modulation of cell cycle progression and reduced migration. Moreover, the distinct metabolomic profiles of the two preparations suggest that differences in their bioactive composition may contribute to their biological activities. These findings provide in vitro evidence of the biological activity of LPP and BLP in breast cancer cell lines and support their potential as safe microbiome-based complementary agents for breast cancer prevention and therapy.
No takes yet. Share an insight, caveat, or question.
Straface et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: